利培酮治疗首发精神分裂症患者疗效的Meta分析
Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.
作者信息
Yang Hua, Wu Haili
机构信息
Department of Psychiatry, Hainan Anning Hospital, Haikou, China.
Department of nursing, The First Affiliated Hospital of Hainan Medical College, Hai-kou, China.
出版信息
Noro Psikiyatr Ars. 2024 Nov 30;61(4):351-357. doi: 10.29399/npa.28712. eCollection 2024.
INTRODUCTION
First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia.
METHODS
A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed.
RESULTS
A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone.
CONCLUSION
Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.
引言
首发精神分裂症是一种病因复杂的常见精神障碍。本荟萃分析评估利培酮治疗首发精神分裂症患者的疗效。
方法
进行文献检索以确定关于利培酮治疗首发精神分裂症疗效的研究。对文献质量进行评估，然后进行荟萃分析。
结果
共纳入15篇文章（6篇中文和9篇英文）。荟萃分析显示，与对照组相比，利培酮的治愈率（相对危险度[RR]=0.51，95%置信区间[CI]：0.46 - 0.57，p<0.001）和总显著改善率（RR=0.58，95%CI：0.52 - 0.65，p<0.001）有统计学显著差异，表明利培酮优于对照组。利培酮导致体重增加（p<0.001）和锥体外系症状（p=0.005）的发生率更高。
结论
在治疗首发精神分裂症患者方面，与对照组（包括安慰剂和其他抗精神病药物）相比，利培酮显示出更高的治愈率和有效率。然而，它可能会增加锥体外系反应和体重增加的风险。
Zotero 插件